Posted by Michael Wonder on 03 Nov 2020
Gilead faces pressure to relinquish valuable FDA voucher awarded with remdesivir approval
2 November 2020 - A prominent advocacy group is asking Gilead Sciences to relinquish a valuable voucher that came with FDA approval of its remdesivir treatment for COVID-19, arguing the voucher is “an entirely unnecessary and an inappropriate incentive” for a drug that has “limited” effectiveness and is already generating huge profits.
In a letter to Gilead, Public Citizen maintained the priority review voucher — which the FDA awarded for developing a drug that posed a “material threat” to public health — offers the company an undeserved windfall.
